MARKET

KTRA

KTRA

Kintara Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.300
-0.100
-7.14%
After Hours: 1.290 -0.01 -0.77% 19:19 09/20 EDT
OPEN
1.343
PREV CLOSE
1.400
HIGH
1.390
LOW
1.270
VOLUME
510.30K
TURNOVER
--
52 WEEK HIGH
3.350
52 WEEK LOW
1.180
MARKET CAP
42.40M
P/E (TTM)
-0.6169
1D
5D
1M
3M
1Y
5Y
BRIEF-Kintara Therapeutics Provides Positive Site Activation Update On Gcar Phase 2/3 Clinical Trial For Glioblastoma
reuters.com · 08/17 12:14
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research...
PR Newswire · 08/17 12:00
Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021
Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that its Chief Executive Officer, Saiid Zarrabian, will pr...
PR Newswire · 08/12 12:00
10 Biotech Penny Stocks to Buy According to Reddit
In this article, we discuss the 10 biotech penny stocks to buy according to Reddit. If you want to skip our detailed analysis of these stocks, go directly to the 5 Biotech Penny Stocks to Buy According to Reddit. Innovation and advancements in science and ...
Insider Monkey · 08/06 14:20
Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021
/PRNewswire/ -- . (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that , Chief Executive Officer, will participate at the BTIG Virtua...
PR Newswire - PRF · 08/04 12:00
KTRA: Phase II Topline
By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT
Benzinga · 07/14 10:31
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap...
Benzinga · 07/09 21:20
Kintara Therapeutics Shares See Volume; Zacks SCR Issues Report On Co's Phase 2 Topline Results
https://scr.zacks.com/news/news-details/2021/KTRA-Phase-II-Topline-article/default.aspx
Benzinga · 07/09 14:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KTRA. Analyze the recent business situations of Kintara Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KTRA stock price target is 5.81 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 2.76M
% Owned: 8.46%
Shares Outstanding: 32.62M
TypeInstitutionsShares
Increased
9
804.46K
New
8
191.78K
Decreased
2
410.40K
Sold Out
3
66.87K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
Robert Hoffman
President/Chief Executive Officer/Director
Saiid Zarrabian
Chief Financial Officer
Scott Praill
Chief Scientific Officer
Dennis Brown
Vice President - Research & Development
Steve Rychnovsky
Independent Director
Laura Johnson
Independent Director
Keith Murphy
Independent Director
Tamara Seymour
Independent Director
Robert Toth
No Data
About KTRA
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The Company is carrying out various clinical trials on brain tumor and solid tumor.

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.